Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today highlighted its 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback